glp 1 va study Large Analysis of Veterans With Diabetes: More Benefits with GLP-1RA, Especially Neurological GLP-1 was approved as a

The study looked at data from more than 50,000 patients being treated for type 2 diabetes using electronic patient data from the University of Pennsylvania Health System

Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT

D-Allulose reduces weight more persistently than oral semaglutide while both equally elevate grip strength in diet-induced obese mice

W.FilizG.MastersC

[1] [5] While most GLP-1 medications are administered via subcutaneous injection (such as semaglutide, liraglutide, dulaglutide, or tirzepatide), with oral semaglutide (Rybelsus) as the only FDA-approved non-injectable option, transdermal patch delivery systems represent an emerging area of pharmaceutical development